NEW YORK (GenomeWeb) – Molecular diagnostics firm Great Basin Scientific today announced it has submitted a 510(k) application to the US Food and Drug Administration for marketing clearance of its Group B Strep assay for perinatal infections.

The sample-to-result assay is used to detect Streptococcus agalactiae from vaginal and rectal swabs collected from antepartum women around weeks 35 to 37 of pregnancy. The results help physicians determine if the woman needs antibiotic treatment to help prevent transmission of an infection during child birth.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.